Speaker: Christian Köse Fisher, Hans Henrik Pontoppidan
Location: H-Lundbeck A/S HQ in Valby
China’s pharmaceutical, biotech, and medtech sectors are experiencing rapid growth, driven by a dynamic and evolving R&D landscape. Increased local investment is fueling new and groundbreaking research across clinical stages, creating both risks—such as data privacy and IP concerns—and significant opportunities for collaboration with Chinese partners.
This meeting explores these developments across pharma/biotech and medtech, focusing on the potential for partnerships and the broader implications of this shifting landscape.
NB: This meeting will be conducted under the Chatham House Rule and is open by invitation only to DCBF members.
